The short answer
Native GHRH clears in minutes, dominated by DPP-4. Modified GRF (1-29) extends that to roughly thirty minutes by blocking DPP-4 and other cleavage sites. The DAC form extends it to days by binding covalently to albumin, which removes renal filtration as a route.
Key facts
- Native GHRH
- Minutes (DPP-4 dominated)
- Modified GRF (1-29)
- ~30 minutes
- CJC-1295 with DAC
- Days
- DPP-4 countermeasure
- D-Ala at position 2
- Renal countermeasure
- Covalent albumin binding
- Albumin half-life
- ~19 days
Three clearance problems, solved in sequence
Native GHRH faces enzymatic cleavage and renal filtration. The substitutions address the first: D-alanine at position 2 makes the peptide a non-substrate for DPP-4, and three further substitutions cover other cleavage points. That alone takes it from minutes to about thirty minutes, a real gain, and still short, because the molecule remains small enough to be filtered.
Why size still matters after the substitutions
At 3367.9 Da, Modified GRF (1-29) passes the glomerulus freely. Blocking proteases does nothing about that. To extend duration further, something has to make the molecule effectively larger in circulation, which is exactly what the DAC linker achieves by attaching it to a 66 kDa protein.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
Covalent versus reversible, and why it matters here
Semaglutide's fatty acid binds albumin reversibly, maintaining an equilibrium between free and bound. DAC forms a covalent bond to albumin's cysteine-34. The peptide is not in equilibrium. It is attached, and its duration is governed by albumin turnover rather than by a dissociation constant. Albumin's half-life is around nineteen days, which is why the DAC form lasts days rather than hours.
The physiological question that creates
GHRH signalling is normally pulsatile, and a covalently albumin-bound analogue produces sustained receptor exposure instead. Whether continuous stimulation produces the same downstream result as pulses is a real question, and Ionescu and Frohman addressed it directly in 2006, reporting that pulsatile GH secretion persists during continuous stimulation, the pituitary imposing its own rhythm on a constant signal.
Why the non-DAC form is not simply inferior
A short half-life is a design choice, not a defect. If the research question concerns a brief physiological-like pulse, a compound clearing in thirty minutes models that better than one producing continuous exposure for days. Which is appropriate depends entirely on what is being studied.
Frequently asked questions
Why is the DAC form so much longer-acting?
It binds covalently to albumin, so its duration tracks albumin turnover (around nineteen days) rather than its own clearance.
Do the substitutions alone give a long half-life?
No. They block enzymatic cleavage but not renal filtration, which is why Modified GRF (1-29) still clears in about thirty minutes.
Does continuous stimulation change GH release?
Ionescu and Frohman reported that pulsatile GH secretion persists during continuous stimulation, with the pituitary imposing its own rhythm.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedIonescu M & Frohman LA, Pulsatile GH secretion persists during continuous stimulation. J Clin Endocrinol Metab 2006 (PMID 17018654)pubmed.ncbi.nlm.nih.gov
- PubMedTeichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 (CID 91971820)pubchem.ncbi.nlm.nih.gov
- PubMedRaun et al., Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 / mod GRF (1-29) (CID 56841945)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- What Is Ipamorelin? Sequence, Receptor and SelectivityIpamorelin is a five-residue ghrelin receptor agonist, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described as the first selective growth hormone secretagogue.
- How CJC-1295 Works as a GHRH AnalogueCJC-1295 agonises the GHRH receptor on pituitary somatotrophs. Why the substitutions matter and what continuous versus pulsatile stimulation implies.
- Why These Two Are Studied TogetherTwo receptors, one output. The mechanistic rationale for pairing a GHRH analogue with a ghrelin receptor agonist - and what would be needed to test it.
- What the Published Literature ContainsTwo human pharmacokinetic studies from 2006, a 1998 selectivity paper, and comparatively little else. A small but unusually clinical evidence base.
- Storage and Reconstitution for Both CompoundsTwo peptides differing fivefold in mass, stored together but not identical. Why the DAC form's maleimide is the one genuinely reactive feature here.